-
公开(公告)号：WO2017097990A1
公开(公告)日：2017-06-15
申请号：PCT/EP2016/080462
申请日：2016-12-09
申请人： PHILOGEN S.P.A.
发明人： WULHFARD, Sarah , VILLA, Alessandra , PEMBERTON ROSS, Catherine , PRETTO, Francesca , FLEETWOOD, Filippa
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/40 , C07K2317/21 , C07K2317/33 , C07K2317/528 , C07K2317/60 , C07K2317/622 , C07K2317/92
摘要： The invention relates to the diagnosis and treatment of diseases,including inflammatory disorders, proliferative disorders and autoimmune diseases. The invention provides, and involves the use of, antibody molecules that bind: i) lysozyme, ii) neutrophil elastase, iii) tissue inhibitor of metalloproteinase-1 (TIMP-1), or iv) the D domain of Tenascin-C. The invention also relates to the use of antibody molecules that bind v) the IIICS isoform of fibronectin, vi) the Extra Domain-B (ED-B) of fibronectin, vii) matrix-metalloproteinase 3 (MMP3), or viii) the A1 domain of tenascin-C in the diagnosis and treatment of inflammatory disorders such as inflammatory bowel disease.
摘要翻译： 本发明涉及疾病的诊断和治疗，包括炎性疾病，增殖性疾病和自身免疫性疾病。 本发明提供并涉及结合i）溶菌酶，ii）嗜中性粒细胞弹性蛋白酶，iii）金属蛋白酶-1的组织抑制剂（TIMP-1）或iv）腱生蛋白-C的D结构域的抗体分子的用途。 本发明还涉及结合v）纤连蛋白的IIICS同种型，vi）纤连蛋白的额外结构域-B（ED-B），vii）基质金属蛋白酶3（MMP3），或viii）A1 腱生蛋白-C在炎症性肠病等炎症疾病的诊断和治疗中的应用。
-
公开(公告)号：WO2019122025A1
公开(公告)日：2019-06-27
申请号：PCT/EP2018/086001
申请日：2018-12-19
申请人： PHILOGEN S.P.A
发明人： GUALANDI, Laura , WULHFARD, Sarah , PRETTO, Francesca , PEMBERTON-ROSS, Catherine , VILLA, Alessandra , DE LUCA, Roberto
摘要： The present application relates to specific binding members that bind carbonic anhydrase IX (CAIX). In particular, the present application relates to the treatment, diagnosis and detection of tumours, e.g. solid tumours, using specific binding members that bind CAIX. The specific binding member may be conjugated to a biocidal or cytotoxic molecule, or to a detectable label.
-
公开(公告)号：WO2017121880A1
公开(公告)日：2017-07-20
申请号：PCT/EP2017/050725
申请日：2017-01-13
申请人： PHILOGEN S.P.A
发明人： VILLA, Alessandra , PEMBERTON ROSS, Catherine , PRETTO, Francesca , FLEETWOOD, Filippa , FUGMANN, Tim
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/2851 , C07K16/40 , C07K2317/21 , C07K2317/33 , C07K2317/622 , C07K2317/92
摘要： The present invention relates to the treatment of intestinal diseases and disorders, such as inflammatory bowel disease (IBD). The invention involves antibodies and the use of antibodies which bind antigens that have been shown to be over-expressed in the intestine compared to other organs, including antigens cadherin-17, anterior gradient protein 2 homolog, galectin-4, and galectin-2. The antibodies may be conjugated to anti-inflammatory or immunosuppressive agents, as required.
摘要翻译： 本发明涉及肠道疾病和病症如炎症性肠病（IBD）的治疗。 本发明涉及抗体和抗体的用途，所述抗体结合与其他器官（包括抗原钙粘蛋白-17，前面梯度蛋白质2同系物，半乳糖凝集素-4和半乳糖凝集素-2）相比已显示在肠中过表达的抗原。 根据需要，抗体可以与抗炎剂或免疫抑制剂缀合。
-
公开(公告)号：WO2018069467A1
公开(公告)日：2018-04-19
申请号：PCT/EP2017/076116
申请日：2017-10-12
申请人： PHILOGEN S.P.A.
IPC分类号： A61P15/00 , A61K39/395 , C07K14/54 , C07K14/55 , C07K14/705 , C07K16/18 , C07K16/40 , A61K47/68 , A61P17/06 , A61P35/00 , A61P19/02
CPC分类号： A61P15/00 , A61K39/3955 , A61K39/39558 , A61K47/6813 , A61K47/6851 , A61P17/06 , A61P19/02 , A61P35/00 , C07K14/5406 , C07K14/5428 , C07K14/5434 , C07K14/55 , C07K14/70578 , C07K16/18 , C07K16/40
摘要： This invention relates to an immunoconjugate comprising interleukin-4 (IL4) and two antibody molecules which bind an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling, such as the A1 domain of tenascin C or the ED-A or ED-B isoforms of fibronectin. The antibody molecules may be positioned at the N and C terminals of the IL4. The immunoconjugate may be useful in the treatment of cancer, inflammatory autoimmune disease and other disease characterised by expression of an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling.
摘要翻译： 本发明涉及包含白介素-4（IL4）和两种抗体分子的免疫偶联物，所述抗体分子结合与肿瘤生长，血管生成和/或组织重塑有关的细胞外基质成分，如A1 腱生蛋白C的域或纤连蛋白的ED-A或ED-B同种型。 抗体分子可以位于IL4的N和C末端。 免疫缀合物可用于治疗癌症，炎症性自身免疫疾病和其他以表达与肿瘤生长，血管生成和/或组织重塑有关的细胞外基质成分为特征的疾病。
-
公开(公告)号：WO2018069467A9
公开(公告)日：2018-04-19
申请号：PCT/EP2017/076116
申请日：2017-10-12
申请人： PHILOGEN S.P.A.
IPC分类号： A61P15/00 , A61K39/395 , C07K14/54 , C07K14/55 , C07K14/705 , C07K16/18 , C07K16/40 , A61K47/68 , A61P17/06 , A61P35/00 , A61P19/02
摘要： This invention relates to an immunoconjugate comprising interleukin-4 (IL4) and two antibody molecules which bind an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling, such as the A1 domain of tenascin C or the ED-A or ED-B isoforms of fibronectin. The antibody molecules may be positioned at the N and C terminals of the IL4. The immunoconjugate may be useful in the treatment of cancer, inflammatory autoimmune disease and other disease characterised by expression of an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling.
-
公开(公告)号：WO2016180715A1
公开(公告)日：2016-11-17
申请号：PCT/EP2016/060128
申请日：2016-05-05
申请人： PHILOGEN S.P.A.
IPC分类号： C07K14/525 , C07K14/55 , C07K16/18 , C07K19/00 , A61P35/00
CPC分类号： C07K14/525 , A61K38/00 , A61K47/6813 , A61K47/6851 , A61P35/00 , C07K14/55 , C07K16/18 , C07K2317/622 , C07K2317/73 , C07K2319/33 , C07K2319/74 , C07K2319/75
摘要： The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNFα), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.
摘要翻译： 本申请涉及包含白细胞介素2（IL2）和肿瘤坏死因子（例如肿瘤坏死因子α（TNFα））和抗体分子的缀合物。 抗体分子优选结合与肿瘤生长和/或血管发生相关的抗原，例如纤连蛋白的外域A（EDA）。 缀合物可用于治疗癌症。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.01 秒)
